FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200188161> ?p ?o ?g. }

• W4200188161 abstract "The World Health Organization recommends dolutegravir (DTG) as the for first-line and second-line antiretroviral therapy (ART) worldwide. However, little is known about the acceptability and tolerability of DTG-based ART at routine points-of-care in Uganda. We set out to explore the perceptions of clinicians in ART clinics regarding the acceptability and tolerability of DTG-based ART since national roll-out in March 2018 in Uganda.We adopted a qualitative exploratory design involving 49 participants. Between September 2020 and February 2021, we conducted 22 in-depth interviews with clinicians in the ART clinics of 12 purposively selected health facilities across Uganda. The selection of study sites ensured diversity in facility ownership-type (public/private), level of service delivery (tertiary/secondary/primary) and the four major geographic sub-regions of Uganda. We conducted three focus group discussions with 27 clinicians in the participating facilities. Data were analyzed by thematic approach.Clinicians in ART clinics acknowledged that DTG-based ART is well tolerated by the majority of their patients who appreciate the reduced pill burden, perceived less side effects and superior viral load suppression. However, they reported that a number of their patients experience adverse drug reactions (ADRs) after being transitioned to DTG. Hyperglycemia is, by far, the most commonly reported suspected ADR associated with DTG-based regimens and was cited in all but two participating facilities. Insomnia, weight gain and reduced libido are among the other frequently cited suspected ADRs. In addition, clinicians in ART clinics perceived some of the suspected ADRs as resulting from drug interactions between dolutegravir and isoniazid. Weak diagnostic capacities and shortage of associated commodities (e.g. glucometers and test kits) were reported as impediments to understanding the full extent of ADRs associated DTG-based ART.While DTG-based regimens were perceived by clinicians in ART clinics to be well tolerated by the majority of their patients, they also reported that a number of patients experience suspected ADRs key among which were hyperglycemia, insomnia and reduced libido. Based on the perspectives of clinicians, we recommend that future studies examine the prevalence of dolutegravir-induced hyperglycemia in patients in Uganda." @default.
• W4200188161 created "2021-12-31" @default.
• W4200188161 creator A5033916367 @default.
• W4200188161 creator A5044167154 @default.
• W4200188161 creator A5057247852 @default.
• W4200188161 creator A5070817307 @default.
• W4200188161 creator A5077080886 @default.
• W4200188161 creator A5080569443 @default.
• W4200188161 date "2021-12-01" @default.
• W4200188161 modified "2023-10-06" @default.
• W4200188161 title "Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study" @default.
• W4200188161 cites W122464911 @default.
• W4200188161 cites W1533537857 @default.
• W4200188161 cites W1924618820 @default.
• W4200188161 cites W1973468469 @default.
• W4200188161 cites W2009641600 @default.
• W4200188161 cites W2018393126 @default.
• W4200188161 cites W2072080151 @default.
• W4200188161 cites W2074344667 @default.
• W4200188161 cites W2089197323 @default.
• W4200188161 cites W2112049615 @default.
• W4200188161 cites W2133674686 @default.
• W4200188161 cites W2163899650 @default.
• W4200188161 cites W2276165593 @default.
• W4200188161 cites W2536125416 @default.
• W4200188161 cites W2580771560 @default.
• W4200188161 cites W2582406074 @default.
• W4200188161 cites W2617292252 @default.
• W4200188161 cites W2727072348 @default.
• W4200188161 cites W2728117782 @default.
• W4200188161 cites W2741695407 @default.
• W4200188161 cites W2766138644 @default.
• W4200188161 cites W2795455208 @default.
• W4200188161 cites W2883729505 @default.
• W4200188161 cites W2891488238 @default.
• W4200188161 cites W2892058425 @default.
• W4200188161 cites W2901087969 @default.
• W4200188161 cites W2902025352 @default.
• W4200188161 cites W2903165386 @default.
• W4200188161 cites W2922248162 @default.
• W4200188161 cites W2945985905 @default.
• W4200188161 cites W2960767487 @default.
• W4200188161 cites W2967602084 @default.
• W4200188161 cites W2969926586 @default.
• W4200188161 cites W2982193890 @default.
• W4200188161 cites W2989885432 @default.
• W4200188161 cites W3006965005 @default.
• W4200188161 cites W3010785869 @default.
• W4200188161 cites W3029227667 @default.
• W4200188161 cites W3032571821 @default.
• W4200188161 cites W3046474211 @default.
• W4200188161 cites W3084760442 @default.
• W4200188161 cites W3099682630 @default.
• W4200188161 cites W3113221469 @default.
• W4200188161 cites W3119111511 @default.
• W4200188161 cites W3191427281 @default.
• W4200188161 cites W3194968367 @default.
• W4200188161 cites W4295093016 @default.
• W4200188161 doi "https://doi.org/10.1186/s12879-021-06933-8" @default.
• W4200188161 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34876050" @default.
• W4200188161 hasPublicationYear "2021" @default.
• W4200188161 type Work @default.
• W4200188161 citedByCount "2" @default.
• W4200188161 countsByYear W42001881612022 @default.
• W4200188161 crossrefType "journal-article" @default.
• W4200188161 hasAuthorship W4200188161A5033916367 @default.
• W4200188161 hasAuthorship W4200188161A5044167154 @default.
• W4200188161 hasAuthorship W4200188161A5057247852 @default.
• W4200188161 hasAuthorship W4200188161A5070817307 @default.
• W4200188161 hasAuthorship W4200188161A5077080886 @default.
• W4200188161 hasAuthorship W4200188161A5080569443 @default.
• W4200188161 hasBestOaLocation W42001881611 @default.
• W4200188161 hasConcept C126322002 @default.
• W4200188161 hasConcept C142462285 @default.
• W4200188161 hasConcept C144024400 @default.
• W4200188161 hasConcept C144133560 @default.
• W4200188161 hasConcept C159110408 @default.
• W4200188161 hasConcept C160735492 @default.
• W4200188161 hasConcept C162324750 @default.
• W4200188161 hasConcept C162853370 @default.
• W4200188161 hasConcept C190248442 @default.
• W4200188161 hasConcept C197934379 @default.
• W4200188161 hasConcept C2778375690 @default.
• W4200188161 hasConcept C2779502633 @default.
• W4200188161 hasConcept C2993143319 @default.
• W4200188161 hasConcept C3013748606 @default.
• W4200188161 hasConcept C36289849 @default.
• W4200188161 hasConcept C50522688 @default.
• W4200188161 hasConcept C512399662 @default.
• W4200188161 hasConcept C56995899 @default.
• W4200188161 hasConcept C71924100 @default.
• W4200188161 hasConcept C74196892 @default.
• W4200188161 hasConcept C81603835 @default.
• W4200188161 hasConceptScore W4200188161C126322002 @default.
• W4200188161 hasConceptScore W4200188161C142462285 @default.
• W4200188161 hasConceptScore W4200188161C144024400 @default.
• W4200188161 hasConceptScore W4200188161C144133560 @default.
• W4200188161 hasConceptScore W4200188161C159110408 @default.
• W4200188161 hasConceptScore W4200188161C160735492 @default.
• W4200188161 hasConceptScore W4200188161C162324750 @default.

• next